Infitek Poct Fully Immunofluorescence Quantitative Analyzer

• Type: Immunofluorescence Quantitative Analyzer
• Transport Package: High Quality Carton
• Specification: 500x400x400mm
• Trademark: Infitek
• Origin: China
• Model NO.: IFA-Q-1000

Product Description

POCT Fully Immunofluorescence Quantitative Analyzer

Features

POCT Fully Quantitative Immunofluorescence Analyzer
Most Stable Rare Earth Material Time-Resolved
Immunofluorescence Methodology
Top Quality POCT Immunofluorescence Platform
Platform Features
Sample Types: Serum, Whole Blood, Plasma, Fingertip Blood, Urine…
Parameters:Diabetes,Kidney Function,Infection,Cardiac Function,Gastric Function…
Comprehensive
Various assays
Comprehensive sample types
Simple and Convenient
Small size, space -saved, stacked incubators
Convenient operation, no requirement for professional skills
Accuracy
Constant incubation, corruption prevention,
low coefficient variance Precise quality control, accurate results
Rapidity
Point of care testing
Instant results analysis in 10 seconds

Specification

Subject	Performance parameter
Detection speed	10 sec/test
Time of first result	5-15min
Sample position	8 channel (stackable)
LIS system	Support ASTM and HL7
Packaging Size(mm)	500x400x400mm
Net/Gross Weight	8.5/9kg
Control	Embedded integrated machine
Interface	Graphical operation interface
Status monitor	Real-time intelligent monitoring
Repeatability	CV≤15%
Fluorescence Rare Earth Fluorescence life-span is longer than Quantum Fluorescence with no disruption and high accuracy
Fluorescent materials	Life-span
Fluorescent rare earth	714000 ns
Quantum	20-50 ns
Nonspecific fluorescent particle	1-10 ns

Rare earth fluorescence has larger stokes shift, higher signal-to noise ratio (SNR) and higher sensitivity compared to other markers

Rare earth fluorescence has high quantum yield, high fluorescent efficiency, and wide linear range

Menu of assays

Biomarkers		Abbr.	Specimen	Instruction for Use	Expected values	Measuring range
Inflammation	Procalcitonin	PCT	Serum/Whole Blood	lndicate sepsis and bacterial infection	<0.05 ng/mL	0.05-100 ng/mL
	Full Range C-reactive Protein	CRP	Plasma/Whole Blood	Low risk of cardiovascular disease Medium risk of cardiovascular disease ·High risk of cardiovascular disease Detecting conventional inflammation	hs-CRP:<1.0mg/L hs-CRP:1.0-3.0mg/L hs-CRP:>3.0mg/L CRP:≤10 mg/L	0.5-200 mg/L
	C-reactive Protein/Amyloid proteinase A 2-in-1	CRP/SAA	Plasma/Whole Blood	·Low risk of cardiovascular disease ·Medium risk of cardiovascular disease ·High risk of cardiovascular disease Detecting conventional inflammation	hs-CRP: <10mg/L hs-CRP:1.0-3.0mg/L hs-CRP: >3.0mg/L CRP:≤10 mg/L	0.5-200 mg/L
Immune	Rheumatism 3-in-1	ASO/RF/CRP	Serum/Plasma/ Whole Blood	lndicators of systemic inflammation ·To assist in the diagnosis,classification and prognosis of rheumatoid arthritis	ASO:≤200 IU/mL RF:≤20IU/mL CRP:≤10 mg/L	ASO:50-500 IU/mL RF:10-200 IU/mL CRP:0.5-200 mg/L
	*Anti cyclic citrullinated peptide antibody	Anti-CCP	Serum/Plasma/Whole Blood	·Assistant diagnostic indexe of rheumatoid arthritis	s25 U/mL	25-1000 U/mL
Cardiovascular	Cardiac Troponin I	cTnl	Serum/Plasma/Whole Blood	·Diagnose AMI,risk stratification and evaluate prognosis Value markers of non ST segment elevation MI	≤0.3 ng/mL	0.1-50 ng/mL
	Creatine Kinase-MB	CK-MB	Serum/Plasma/Whole Blood	·Negative exclusion of early AMI; Detection of recurrence and thrombolytic therapy	≤5 ng/mL	1-100 ng/mL
	Myoglobin	MYO	Serum/Plasma/Whole Blood	Early diagnosis of AMI	s70 ng/mL	5-500 ng/mL
	Myocardial Infarction(MI) 3-in-1	cTnl/MYO/ CK-MB	Serum/Plasma/Whole Blood	Same as above 3 markers	cTnl:≤03ng/mL MYO=70 ng/mL CK-MB:≤5ng/mL	cTnl:01-50 ng/mL MYO:5-500 ng/mL CK-MB:1-100 ng/mL
	D-Dimer(D-Dimer)	D-Dimer	Plasma/Whole Blood	Exclusion and diagnosis of venous thromboembolism	≤0.5 mg/L	0.1-10 mg/L
	N-terminal B-type natriuretic peptide	NT-proBNP	Serum/Plasma/Whole Blood	Diagnosis heart failure,risk stratification and prognostic evaluation	≤300 pg/mL	50-35000 pg/mL
	*Lipoprotein-Associated Phospholipase A2	Lp-PLA2	Serum/Plasma/Whole Blood	lndicating the stability of atherosclerotic plaque ·Predicting the risk of coronary heart disease and stroke	s200ng/mL	20-1000 ng/mL
	*cTnl/NT-proBNP/D-Dimer 3-in-1	cTnl/ NT-proBNP/ D-Dimer	Plasma/Whole Blood	Same as above 3 markers	ctnl:s03ng/mL NT-proBNP:≤300 pg/mL D-Dimer:≤0.5 mg/L	cTnl:01-50 ng/mL NT-proBNP:100-20000 pg/mL D-Dimer:0.1-10 mg/L

 

Packaging & Shipping

Certifications

About us

FAQ

Q: How about quality of the goods?

A:

l All the running products comply with CE standards.

l Independent quality inspection team, conducting multiple inspections and random inspections from parts supply to product dispatch.

l Well-known third-party testing service available, such as SGS, BV, and TUV, etc.

 

Q: What are your pre- and after-sales services?

A:

l Timely reply to pre-sales enquiries

l Real-time update of manufacturing and shipment status

l Contracted third-party maintenance company in over 60 countries

Assured availability of parts supply for 10 years at least

 

Q: Is OEM service available.

A: Most of the running products are available for OEM customization, including logo, package and function, if attainable, customization.

 

Q: How long is the lead time:

A: Generally, the lead time for most stocked products is about 7~15 days, vary by models and production schedule. For those non-stocked products, the manufacturing lead time is around 20 days.